ARTICLES BY ANNA ROSE

• The Biosimilar Toolbox: How To Ratchet Up Biosimilar Competition In 2021

  As you’ll read in the following responses, increased competition in 2021 is on the minds of many. How that competition unfolds has yet to be determined. But if one thing is clear, it’s that the industry has many exciting tools at its disposal to bolster biosimilar competition in 2021. 

• The Top 5 Biosimilar Developments Of 2020

  Though 2020 felt like an endless descent into Dante’s Nine Circles of Hell, I wanted to end the year as I typically do: with a column highlighting the most important and positive biosimilar developments from the past 12 months.

• Will These Big Biosimilar Questions Be Answered In 2021?

  Biosimilar Development is back with the highly anticipated second installment of its Editorial Board 2021 Outlook series! Here, the experts address the biggest questions they have going into 2021, as well as some of the events, policies, and corporate strategies they hope will help answer these questions.

• From “Musty Towel” To “Golden Age:” Biosimilars In 2021 And Beyond

  The industry has certainly come a long way since the “great doubt” of 2019. However, I’d argue the biosimilar space still remains on the verge of transformation.

• Biosimilar Experts Reflect On 2020’s Greatest Biosimilar Achievements

  As the amazing members of the Biosimilar Development Editorial Board emphasize here, there is a lot to be thankful for in the biosimilar world. Check out the first of what will be a four-part series showcasing the editorial board’s thoughts on the past year and the year(s) ahead.

• Why Severability Should Be Every Biosimilar Makers’ Rallying Cry In 2021

  In the upcoming months, the Supreme Court will (hopefully) be deciding whether Congress intended for the entire ACA to survive should individual provisions be found unconstitutional. So, for better or worse, the biosimilar industry has a few more months of pondering the (excruciating) “what ifs” around the future of the BPCIA. 

• 3 Expert Perspectives On Biosimilar Differentiation & Biobetter Development

  In part two of this two-part series, several experts from a DIA panel share additional insights around the types of differentiation biosimilar companies can pursue and its overall impact on product/device selection and the manufacturing process. 

• Biosimilar Or Biobetter? Perspectives On An Evolving Market

  A recent webinar from IQVIA on the biosimilar and “biobetter” landscape provided a great overview of the opportunities for differentiation and the outlook for biobetter development. In part one of this two-part article on differentiation, I’ll share some of my main takeaways from IQVIA’s webinar.

• IQVIA’s U.S. Biosimilar Report: Your Most Pressing Questions Answered

  In recent weeks, there have been several reports released on the current state of the U.S. biosimilar market — including IQVIA's "Biosimilars in the U.S. 2020-2024." Overall, there were a few data points from this report I thought were worth singling out and discussing a bit further. 

• The Little-Known Drivers Behind 2020’s (And 2021’s?) Biosimilar Boom

  There were a few efforts discussed during the recent DIA Biosimilars Conference that I wanted to single out as being particularly critical to the inner workings of this market. I’d argue these efforts are just as noteworthy —perhaps even more worthy — of celebrating as biosimilars’ resulting market performance.